Since both breast cancer molecular subtype and clinical subtype are derived from a continuous scale of basal/luminal transcriptomic signatures or HR expression, respectively, we also calculated the correlation between PBMC immune cell abundance, basal/luminal status, and ER/PR expression level that is previously documented by the I-SPY2 tumor analysis17. This evidence concerns the gene PGR and neoplasm.